CereVasc Raises $85M Series C to Advance eShunt Hydrocephalus Treatment
Boston-based CereVasc raised $85M in Series C funding to advance its eShunt System, support the STRIDE trial, and expand hydrocephalus treatment innovation.
CereVasc, a Boston-based clinical-stage medical device company, has raised $85M in Series C funding led by Piper Sandler Merchant Banking. The company is developing the eShunt System, an investigational endovascular treatment for communicating hydrocephalus and normal pressure hydrocephalus (NPH), conditions that have historically relied on invasive surgical interventions.
The financing includes participation from Johnson & Johnson Innovation, JJDC, Inc., Medtronic, Bain Capital Life Sciences, and Perceptive Xontogeny Venture Funds. The new capital will support the company's STRIDE pivotal trial, regulatory advancement, operational scale-up, and preparation for potential commercialization.
What Happened
Some funding rounds are about growth. Some are about survival. Others are about validation. The latest financing for CereVasc falls squarely into the third category.
The company secured an oversubscribed $85M Series C led by Piper Sandler Merchant Banking, with participation from Johnson & Johnson Innovation, JJDC, Inc., Medtronic, Bain Capital Life Sciences, and Perceptive Xontogeny Venture Funds. For a clinical-stage medical device company, attracting this level of strategic and institutional backing is less about the size of the check and more about confidence in the clinical pathway ahead.
CereVasc operates from Boston, one of the world's leading medical device and life sciences ecosystems. The region, supported by organizations such as MassBio, has become a launchpad for companies pursuing some of healthcare's most difficult challenges, particularly where engineering, medicine, and clinical research intersect.
Why CereVasc Matters
Hydrocephalus is one of those conditions that rarely enters public conversation until it becomes deeply personal. For decades, treatment has largely relied on invasive surgical shunts, a standard of care that has helped many patients but continues to carry meaningful complication and revision risks.
The vision behind CereVasc was built around a different question. Could treating communicating hydrocephalus require less surgical intervention while maintaining clinical effectiveness?
That question has guided the work of Daniel Levangie, Co-Founder, President & CEO, Adel Malek, MD, PhD, MBA, Co-Founder & CMO, Carl Heilman, MD, Co-Founder and Neurosurgeon-in-Chief at Tufts Medical Center, and Patrick J. Sullivan, Co-Founder and Board Director.
The result is the eShunt System, an investigational endovascular technology designed to provide an alternative to conventional surgical shunting for hydrocephalus patients. Rather than improving around the edges of an existing approach, CereVasc is attempting to rethink how treatment can be delivered.
Clinical and Regulatory Progress
Investors may write the checks, but in healthcare, data earns the invitation to the meeting. CereVasc reported multicenter NPH data showing clinical improvement in 95% of participants with no device-related serious adverse events through 90 days. The company also announced treatment of its 100th patient and published first-in-human findings in idiopathic intracranial hypertension, demonstrating sustained outcomes through long-term follow-up.
The company has also secured multiple FDA Breakthrough Device Designations, an important milestone for technologies addressing significant unmet medical needs. While a designation is not approval, it often signals that regulators recognize both the need and the potential clinical significance of a new approach.
What Comes Next
The next major milestone is the STRIDE trial, CereVasc's pivotal clinical study evaluating the safety and effectiveness of the eShunt System in patients with normal pressure hydrocephalus. The study represents a critical step in the company's regulatory journey and future commercialization plans.
Supporting that effort is a leadership team that extends beyond the founding group. Executives including DJ Cass, Senior Vice President of Business Development & Strategy, Aaron Levangie, Senior Vice President & General Counsel, Ona Whelove, VP of Clinical Operations, and Chris Dimler, VP of Operations & Engineering, have helped build the operational, clinical, and regulatory infrastructure needed to move a medical technology from concept to potential market adoption.
With $85M in fresh capital, CereVasc plans to advance the STRIDE trial, continue regulatory engagement, scale operations, and prepare for commercialization activities. The larger story is not the financing itself. It is the steady accumulation of clinical evidence, regulatory momentum, and execution discipline around a condition that has seen relatively limited innovation compared with many other areas of medicine.
Frequently Asked Questions
What is CereVasc?
CereVasc is a Boston-based clinical-stage medical device company developing minimally invasive treatments for hydrocephalus and related neurological conditions.
How much funding did CereVasc raise?
CereVasc raised $85M in Series C funding led by Piper Sandler Merchant Banking.
What is the eShunt System?
The eShunt System is an investigational endovascular device designed to treat communicating hydrocephalus and normal pressure hydrocephalus through a minimally invasive procedure.
Who invested in CereVasc's Series C round?
Investors include Piper Sandler Merchant Banking, Johnson & Johnson Innovation, JJDC, Inc., Medtronic, Bain Capital Life Sciences, and Perceptive Xontogeny Venture Funds.
What is the STRIDE trial?
The STRIDE trial is CereVasc's pivotal clinical study evaluating the safety and effectiveness of the eShunt System in patients with normal pressure hydrocephalus.
Has the eShunt System received FDA approval?
No. The eShunt System remains investigational and has not received FDA approval for commercial sale. Information about medical device approvals can be found through the U.S. Food and Drug Administration.
